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INCREASED morbidity and mortality occur regularly Production of lipopolysaccharide- during influenza epidemics. The exact mechan-
isms involved are not well defined but bacterial induced tumour necrosis factor
superinfection of influenza virus infected patients
is considered to play.an important role. In the during influenza virus infection in
present study, the effect of influenza virus infec- mice coincides with viral
tion on in vivo production of turnout necrosis
factor (TNF) in response to bacterial stimuli was replication and respiratory
investigated. Release of TNF in mice infected by oxidative burst an aerosol of influenza virus was significant after
administration of bacterial lipopolysaccharide
(LPS) at 72h, whereas administration of homo-
logous influenza virus produced only modest K.N. Masihi,cA H. Hintelrnann, K. Madaj and
amounts of TNF at 96 h. Significant production of G. Gast
TNF was observed 48h after intravenous adminis-
tration of infectious influenza in response to LPS
but not with the homologous virus. TNF induced
after influenza virus infection could be blocked Robert Koch IRstitute, Nordufer 20, 13353 BerliR,
by a specific murine anti-TNF monoclonal Germany
antibody. Higher TNF production following
aerosol influenza infection correlated with peak
titres of influenza virus in the lungs of infected CACorresponding Author
mice and with enhanced generation of luminol-
dependent chemiluminscence.
Key words: Anti-TNF antibody, Chemiluminescence, Influ-
enza virus, TNF
Introduction Elderly persons and those with underlying
health problems have more severe illness and
Tumour necrosis factor ot (TNFa) is a pleio- increased complications from influenza. Addi-
tropic cytokine produced mainly by macro- tional deaths above the normal winter increase
phages. The potent immunomodulatory occur regularly during influenza epidemics and
properties of TNF include proliferation of B and are used as one of the non-virologic indicators
T
2 lymphocytes, as well as augmentation of cyto- for influenza surveillance.
12 Excess mortality of
3 4 56 toxic T, NK cell, and neutrophil’ activities. In at least 10000 has been documented in each
addition, TNF has been shown to snergize with of the 19 epidemics in the United States from
other cytokines such as interferon-,. These TNF- 1957 to 1986.12 The exact mechanisms involved
associated host defence mechanisms can play a in increased morbidity and mortality during
pivotal role in restricting the spread of microbial influenza infection are not as yet well defined.
pathogens. Bacterial superinfection of influenza virus infec-
There is, however, increasing evidence that ted patients is considered to play an important
excessive and deleterious production of TNF can role in exacerbating virus-associated pathophy-
be triggered during severe episodes of certain siology during influenza epidemics.
3 Influenza
infections. Raised levels of TNF and soluble TNF virus has been shown to induce the production
receptors have been detected during human of TNF, although the exact role of TNF during
immunodeficienc virus (HIV)infection in sero- influenza infection remains unclear. Broncho-
positive patientsy TNF has been associated with alveolar washings obtained from mice infected
enhanced expression of nuclear factor kappa B, with influenza virus contained TNF14 and TNF
activation of HIV long terminal repeat and sub- activity was demonstrated in influenza virus
sequent up-regulated transcription of the virus.9 infected4,5 or influenza neuraminidase
Production of TNF has been shown to be treated
6 macrophages. No attempts have been
increased in chronic hepatitis B virus infection undertaken .to establish whether in vivo influ-
and clinical studies have indicated a proviral enza virus infection induces production of TNF
effect of TNF at higher doses. TNF plays a in response to bacterial stimuli. The present
major role also in the pathogenesis of the septic study was conducted to investigate in vivo TNF
shock syndrome. production in response to LPS in mice admin-
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istered infectious influenza by aerosol or par- to form monolayers. Various dilutions of test
enteral routes, samples and 1 lg of actinomycin D (Sigma
Chemical Company) dissolved in Eagle’s mini-
mum essential medium were added to wells,
Materials and Methods each in a volume of 100 !1. Plates were incu-
bated for 18h at 37C in the presence of 5%
Mice: Four- to 5-week-old female NMRI mice CO2. Following incubation, the wells were
were obtained from the animal facility maintained aspirated and stained with 0.05% crystal violet in
by the Federal Health Office. 20% ethanol for 15 min. After thoroughly
washing the cells with distilled water, the plates
Pretreatment with influenza virus: Influenza A/ were air dried. The stained cells were solubilized
PR/8/34 (HIN1) was grown in the allantoic cavity by adding 250 1 of ethylene glycol monomethyl
of l1-day embryonated eggs using standard pro- ether to each well. The plates were shaken in
cedures. Infectious virus was administered to the dark for l h and the optical density was
mice using a 1-2 Im diameter particle aerosol of read at 600 nm in a Microplate Reader MR700
mouse-adapted influenza virus in a Middlebrook spectrophotometer (Dynatech). The percentage
Airborne Infection Apparatus (Tri-R Instruments, cytotoxicity was determined. Units of TNF were
Rocklle Center, USA). A 6 ml suspension of calculated by plotting the regression lines of the
influenza virus was nebulized at 20C using a log of the reciprocal dilution of the test sample
venturi nebulizer. The LD50 for mice was 10-4.5 VS. the percentage cytotoxicity. One unit equals
by the intranasal and 10-v by the aerosol route, the highest reciprocal of the supernatant dilution
Some groups of animals received 10 1 000 hae- which resulted in 50% lysis.
magglutinin units of infectious virus by the intra-
venous (i.v.)route. Treatment with anti-TNF monoclonal antibody:
Test dilutions of 1:5 serum samples in a volume
Determination of influenza virus in lungs: Lung of 50 l.tl were mixed thoroughly with the same
virus titres were determined at various time inter- volume of murine anti-TNF monoclonal antibody vals after influenza aerosol infection. Lungs from (kindly provided by BASF, Ludwighafen, five mice were removed intact, rinsed in sterile Germany) containing 125 units. Test serum
saline and quickly frozen at-70C. After thawing, alone, anti-TNF alone and normal mouse serum
lungs were homogenized in a tissue grinder in 1 plus anti-TNF antibody were also included in the
ml of cold MEM medium containing 10% fetal panel. Sera were incubated for 1 h at 37C with
calf serum and antibiotics for each lung. Ten-fold gentle shaking every 15 min. The plates were
dilutions of each supernatant obtained after cen- placed for 30 min at 4C and the TNF assay was
trifugation of the lung homogenate were inocu- performed as described above.
lated in 25 !1 amounts into confluent monolayers
of MDCK cells in 24-well microtitre plates. Quad-
ruplicate cultures were set up for each dilution. Chemiluminescence assay: Aliquots of 500 !1 of
The virus titre was determined 2 days later by spleen cell suspensions in round-bottomed vials
haemadsorption with chicken red blood cells, were mixed with 10 !1 of luminol at a con-
The results are expressed as logm of 50% tissue centration of 1 mg/ml in phosphate buffered
culture infective doses (TClD) calculated accord- saline containing 0.4 triethylamine and incubated
ing to the Reed and Muench method, at 37C for 10 min. Chemiluminescence (CL)
measurements were performed at 37 C in a
Treatment with lipopolysaccharide (LPS): Mice specially developed Biolumat model 9505
pretreated with influenza virus were administered (Berthold, Wildbad, Germany) which permits
25 l.tg of phenol-chloroforom-petroleum ether simultaneous reading of six samples. After the
extracted LPS from Salmonella minnesota measurement of background for 3 min, CL was
(Sigma Chemical Company) by the intravenous generated by addition of 10 I1 of particulate
route at various time intervals. Animals were bled stimuli zymosan (Sigma) suspended in buffered
from the retro-orbital plexus 1.5-2h later and saline at a concentration of 50 mg/ml. CL was
sera were stored at-20C, continuously monitored on a programmed
microcomputer.
TNF bioassay: TNF activity in serum samples was
determined by a standard fibroblast cytotoxicity Statistical analysis: Results are expressed as
assay. Briefly, 100 I1 of 2.5 x 10
4 cells per ml of mean 4- S. D. Statistical comparison with appro-
a sensitive L929 cell line were added to 96-well priate control groups was performed using two-
microtitre plates (NUnc) and incubated overnight tailed Student’s t-test.
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Table 1. Effect of murine anti-TNF monoclonal antibody on
influenza virus induced TNF
Serum group Anti-TNF treatment TNF activity (%)
Influenza + LPS No 100
Influenza + LPS Yes 8
Control No 0
Control Yes 0
None (saline) Yes 0
Mice infected with an aerosol of influenza virus were
administered LPS by the intravenous route 72 h after infection.
Serum dilutions of 1:5 were mixed with 125 units of anti-TNF
monoclonal antibody, incubated and tested in a TNF bioassay.
24h 48h 72h 96h +7d 24h 48h 72h 96h +7d
550 Trigger: LPS Trigger: A/PR/8/34
500
FIG. 1. Production of TNF after aerosol A/PR/8/34 influenza 450
virus infection. LPS or homologous virus were administered == 400
intravenously as a trigger at various times after aerosol influenza
infection. =
350
_’ 300
250
Results ..= oo
150
Kinetics of TNF induction in mice infected by 100
aerosol influenza virus in response to LPS: 50
Animals administered an aerosol of influenza
virus received an injection of LPS by the i.v.
route (five mice per group) after 24, 48, 72 and
24h 48h 72h 96h +7d
Time
96 h, and at 7 days. Sera collected 90-120 min FIG. 2. Zymosan-stimulated chemiluminescence response of
after LPS administration were tested for the pre- splenic phagocytic cells from aerosol influenza virus infected
sence of TNF activity. The results presented in mice administered LPS by the intravenous route.
Fig. 1 show significant production of TNF 72 h
after influenza virus infection (p< 0.0012). A
low, but detectable amount of TNF was pro- at 24, 48, 72, 96 h, and at 7 days. The functional
duced 96 h after influenza infection (P < activity of macrophages was assayed by zymosan-
0.0027). When aerosol influenza infected mice stimulated CL which was performed at the times
were given an i.v. trigger with homologous influ- indicated above. The results presented in Fig. 2
enza A/PR/8/34 virus instead of LPS, a modest show that peak CL response occurred at 72 h (p
amount of TNF was induced only at 96h (p < < 0.0004) followed by 96 h (p < 0.0016) time
0.0122) as is shown in Fig. 1. The levels of TNF intervals after influenza virus infection. Influenza
production in uninfected mice after i.v. injection infected mice without LPS administration gener-
of LPS from Salmonella minnesota were of a ated CL levels which did not differ significantly
low magnitude when compared with the 72 h- from those of uninfected controls (data not
primed influenza group, and did not exceed 52 shown).
units/ml. Similar amount of LPS from virulent
Escherichia coli can induce substantial release of Lung virus titres in mice infected by aerosol
TlX. influenza virus: The amount of virus present in
The specificity of TNF induced by influenza the lungs was determined by titration of lung
virus was tested using an anti-TNF monoclonal homogenates on confluent monolayers of MDCK
antibody. TNF induced 72 h after influenza virus cells. The results presented in Fig. 3 show the
infection could be blocked by a specific murine presence of detectable virus at all time periods
anti-TNF monoclonal antibody, as is shown in tested. Infectivity titres from the lungs of mice
Table 1. infected by aerosol influenza virus but not
treated with LPS were comparable to those
Chemiluminescence response of mice infected by obtained in the 24h group (data not shown).
aerosol influenza virus: Animals in groups of Peak virus titres after influenza infection were
five were infected by an aerosol of influenza detected after 72 h and were followed by the 96 h
virus and LPS was administered by the i.v. route group.
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FIG. 3. Virus titres in lungs of aerosol influenza virus infected
mice administered LPS by the intravenous route.
Kinetics of TNF induction after intravenous
influenza virus infection in mice: Animals in
groups of five were injected with 10, 100, 500 or
6.000
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Trigger: LPS Trigger: A/PR/8/34
FIG. 4. Production of TNF after intravenous administration of dif-
ferent doses of A/PR/8/34 influenza virus. LPS or homologous
virus were administered intravenously as a trigger 48 h after
influenza infection.
The role of TNF in viral infections is dichot-
1000 haemagglutinin units of infectious influenza omous, exhibiting both beneficial and deleter-
virus by the i.v. route. Forty-eight h later, animals ious activities. A variety of cell lines from diverse
received 25 lag of LPS or 1000 haemagglutinin sources could be protected by TNF against infec-
units of infectious A/PR/8/34 influenza virus also tions by vesicular stomatitis virus, encephalomyo-
by the i.v. route. In preliminary experiments, the carditis virus, adenovirus and herpes simplex
LPS trigger, administered by the i.v. route at 24, virus.7’18’19 On the other hand, TNF has been
48, 72 and 96 h, and at 7 days, induced a sig- shown to exacerbate several other viral infections
nificant production of TNF at 48 h after i.v. influ- including those caused by HIV. Primary blood
enza administration (data not shown). The monocyte-derived macrophages treated with
results presented in Fig. 4 show induction in a recombinant human TNF starting before or after
dose-dependent manner of TNF. Peak TNF titres HIV infection enhanced viral replication of both
were obtained by priming with 1000 haemagglu- lymphocyte-tropic and macrophage-tropic
tinin units of influenza virus (p < 0.0005). Com- strains,i Recombinant TNF has been shown to
parable TNF amounts were present in sera of activate HIV mRNA,
21 increase replication,
22 and
animals receiving 500 (p < 0.0001) or 100 (p < enhance syncytium formation2 in T-cell lines.
0.0001) haemagglutinin units of influenza virus. A Simian varicella virus-infected monkeys given TNF
trigger with homologous A/PR/34 virus was not showed increased mortality,
24 and porcine
effective in inducing TNF in A/PR/8/34 virus- monocytes treated with TNF showed an increase
primed mice. of African swine fever virus production.
25
The kinetics of TNF production by the influ-
Discussion enza virus exhibited a marked dependence on
the time elapsed after influenza infection and
Influenza virus infection can predispose the administration of LPS. Significant TNF production
host to bacterial superinfection. Human and was evident 72h after aerosol virus infection.
experimental animals infected with influenza TNF can profoundly affect the functional cap-
have been shown to have increased incidence of ability of phagocytic cells, and has been shown
bacterial infections due to diverse bacteria to enhance the response of neutrophils to parti-
26 including Streptococcus species, Escherichia coli culate stimuli,
5 alter surface receptors and
and Haemophilus influenzae.
1 The results of prime for enhanced production of oxygen radi-
the present study demonstrate that in vivo influ- cals.5’ Administration of TNF in mice can result
enza virus infection by the natural aerosol route in an increase of the percentage of splenic mac-
can prime the host for subsequent release of rophages.
27 In the present study, a high level of
TNF in response to bacterial stimuli and also splenic cell CL activity was observed at 72h in
extend previous in vitro observations showing influenza virus-infected animals that had received
LPS-induced potentiation of the production of LPS. It is noteworthy that the time period of
TNF from influenza virus-infected macrophages.
17 enhanced CL coincides with the peak TNF pro-
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duction and correlated with peak titres of influ-
enza virus which were also detected 72 h after
infection.
Influenza virus or viral components have been
shown to stimulate the production of interferon-
728 and IL-1.16’29 In numerous studies, TNF has
been shown to synergize with other cytokines
including interferon-7. The intricate synergistic
interaction between the putative cytokines
released during the period of peak influenza
virus production and resultant sequelae remain
to be elucidated. The results of the present study
suggests that the TNF response of the influenza
virus infected host on the subsequent homo-
logous influenza virus challenge is of a low mag-
nitude. This could be a reflection of the
protection afforded by primary influenza infec-
tion. In contrast, high levels of TNF were
induced in influenza virus infected animals admi-
nistered bacterial LPS. An understanding of the
kinetics required for the influenza virus to sensi-
tize a host for induction of TNF in response to
bacterial stimuli may help define the critical
period when complications could occur in insti-
tutionalized elderly patients and other persons at
risk during influenza epidemics.
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